Lupin Ltd. informed the exchanges that it has launched Potassium Chloride (KCI) for Oral Solution USP, 20 mEq, having received an approval from the United States Food and Drug Administration (USFDA) earlier.
Lupin's Potassium Chloride for Oral Solution USP, 20 mEq, is the generic equivalent of Pharma Research Software Solution, LLC's Potassium Chloride for Oral Solution USP, 20 mEq, and is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
Potassium Chloride for Oral Solution USP, 20 mEq, had an annual sales of ~$90mnin the US (IQVIA MAT September 2019).
Stock View:
Lupin Ltd is currently trading at Rs748.20 up by Rs1.9 or 0.25% from its previous closing of Rs746.30 on the BSE.
The scrip opened at Rs747 and has touched a high and low of Rs754.35 and Rs740.70 respectively. So far 7,35,898 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs33,787.60cr.
No comments